Fig. 6

NCV is effective in human derived tumor models. (a) Scheme of the vaccine vectors and the vaccination protocol. HHK mice were vaccinated with the TK-M285 (Additional file 1: Table S4) or the TK-U11 (Additional file1: Table S5) vaccine vector and splenocytes transferred in Rag2^−/− Il2r^−/− tumor bearing mice on day 35. HHK mice were vaccinated either with the TK-M285 or TK-U11 vector at the indicated time points (V) and splenocytes were transferred on day 35 into Rag2^−/− Il2r^−/− mice bearing tumors (T) of M285 or U11, respectively. (b) Immune responses detected in the splenocytes of HHK vaccinated mice at the time of splenocyte transfer. On the left side, a representative experiment of TK-M285 specific immune response of six HHK mice was restimulated with a pool of the eight neoantigen peptides. On the right side, immune responses specific for TK-U11 from four vaccinated mice, bars are SD, paired matched T-test 2-tailed *p < 0.05. (c) Tumor growth of M285 and U11 tumor models. Five or six tumor bearing mice were injected i.p. with 5 × 10⁶ splenocytes from HHK vaccinated mice on day 10 (dotted line) and tumor growth followed over time, the data are from one of the two experiments performed. Paired T-test 2-tailed *p < 0.05, bars represent SD